FDA 483 - Magna Pharmaceuticals Inc - October 29, 2021

An FDA inspection of Magna Pharmaceuticals Inc. in Louisville, KY, revealed a significant deficiency in their quality system. The firm failed to adequately establish procedures for corrective and preventive actions (CAPA). This indicates a fundamental gap in their ability to address and prevent recurring issues.